Merck & Co., known as MSD outside the U.S. and Canada, announced a strategic research collaboration with Isomorphic Labs on November 19, 2026. The partnership will utilize Isomorphic Labs' proprietary IsoDDE AI engine to identify small molecule candidates for a specific oncology target, with Merck overseeing all subsequent preclinical, clinical, and commercial development.
MSD signed an early-stage AI drug-discovery collaboration with Isomorphic Labs covering a single oncology target, with no upfront payment amount, milestone values or royalty rates disclosed. For a company of Merck's size this research-stage deal is routine pipeline building and gives no quantified change to revenue or earnings outlook.
- • Collaboration announced Nov 19, 2026 to apply Isomorphic Labs' IsoDDE engine to an oncology target of strategic importance
- • No financial terms disclosed; any payments are contingent on distant research, development, regulatory and commercial milestones
- • Forward-looking statement warns pipeline candidates may not gain regulatory approval or commercial success